特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
915016

重症筋無力症 (MG):疫学的予測

Myasthenia Gravis: Epidemiology Forecast to 2028

出版日: | 発行: GlobalData | ページ情報: 英文 27 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.64円
重症筋無力症 (MG):疫学的予測
出版日: 2019年09月30日
発行: GlobalData
ページ情報: 英文 27 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の主要7ヶ国 (米国、ドイツ、フランス、イタリア、スペイン、英国、日本) における重症筋無力症 (MG) の発症状況と今後の見通しについて分析し、疾患の特徴や現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査しております。

第1章 目次

第2章 重症筋無力症 (MG):エグゼクティブサマリー

  • 関連分析
  • 刊行予定の関連分析

第3章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
  • 過去の世界的傾向
  • 予測手法
    • 情報源
    • 予測の前提条件と手法
    • 予測の前提条件と手法:MGの受診済み有病者数
    • 予測の前提条件と手法:MGの受診済み有病者数、重症度別
  • 重症筋無力症 (MG) の疫学的予測 (今後11年間分)
    • MGの受診済み有病者数
    • MGの受診済み有病者数:年齢別
    • MGの受診済み有病者数:男女別
    • MGの受診済み有病者数:重症度別
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表

List of Tables

  • Table 1: Risk Factors and Comorbidities for MG

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018 and 2028
  • Figure 2: 7MM, Diagnosed Prevalence of MG, %, Both Sexes, All Ages, 2018
  • Figure 3: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of MG
  • Figure 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MG by Severity
  • Figure 5: 7MM, Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018
  • Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of MG, N, Both Sexes, All Ages, 2018
  • Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of MG, N, All Ages, 2018
  • Figure 8: 7MM, Diagnosed Prevalent Cases of MG by Severity, N, Both Sexes, All Ages, 2018
目次
Product Code: GDHCER218-19

Diagnosed prevalent cases of Myasthenia Gravis (MG) are forecast to increase in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) from 152,000 cases in 2018 to 169,000 cases in 2028, at an annual growth rate (AGR) of 1.07%. Myasthenia Gravis (MG) is characterized by weakness in eye, limb, and respiratory muscles. Patients have traditionally been divided into two categories: those with generalized disease and those presenting with disease limited to the eye muscles. Cases of Myasthenia Gravis (MG) have increased in recent years due to the growing and aging population.

The increase in prevalent cases of MG is related to the impact of effective treatment, improved diagnostic methods, and prolonged survival from disease. Risk factors for Myasthenia Gravis (MG) include female gender, autoimmune diseases, thymus diseases, and extrathymic cancers such as breast and lung cancers. Smoking is suspected as a major risk factor for Myasthenia Gravis (MG), but there was no conclusive evidence until recently.

According to the September 2019 study by Apinyawasisuk and colleagues published in the American Journal of Ophthalmology, risk of ocular Myasthenia Gravis (MG) converting to generalized Myasthenia Gravis (MG) is higher in smokers compared to non-smokers. This was a retrospective cohort study of patients with ocular Myasthenia Gravis (MG) extracted from the database of the Neuroscience Laboratory in Thailand in the population ages 18 years and older. Based on smoking history, odds of developing generalized Myasthenia Gravis (MG) from ocular Myasthenia Gravis (MG) were almost three times higher in smokers compared to non-smokers.

Generalized Myasthenia Gravis (MG) is the more severe form of the disease, affecting multiple organs, whereas ocular Myasthenia Gravis (MG) only causes weakness in the eye muscles. Most patients start with ocular Myasthenia Gravis (MG) and 12-80% of these cases develop into generalized Myasthenia Gravis (MG) at the later stages.

Further studies are required in different settings and countries to determine if the link between smoking and Myasthenia Gravis (MG) is genuine and also to explore the possible mechanism of action. As smoking is potentially a major risk factor, smoking cessation should be promoted to patients to prevent the risk of developing a more severe form of Myasthenia Gravis (MG).

Within the report "Myasthenia Gravis: Epidemiology Forecast to 2028" epidemiologists have utilized historical data obtained from peer-reviewed articles and population-based studies to build the forecast for the diagnosed prevalent cases of Myasthenia Gravis (MG) in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan). Epidemiologists applied the prevalence of Myasthenia Gravis (MG) drawn from the above source to each country's population to calculate the number of estimated diagnosed prevalent cases for severity according to MGFA classifications respectively.

Scope:

  • The Myasthenia Gravis Epidemiology Report and Model provide an overview of the risk factors and global trends of Myasthenia Gravis (MG) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of MG segmented by age, sex, and severity according to Myasthenia Gravis Foundation of America (MGFA) classifications (Class I, Class II, Class III, Class IV, and Class V) in the 7MM. Additionally, the model includes a 10-year epidemiological forecast for the antibody status of MG.
  • The MG epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy:

The MG Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global MG market.
  • Quantify patient populations in the global MG market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MG therapeutics in each of the markets covered.
  • Understand magnitude of MG population by its severity.

Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Myasthenia Gravis: Executive Summary

  • 2.1. Related Reports
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global and Historical Trends
  • 3.4. Forecast Methodology
    • 3.4.1. Sources
    • 3.4.2. Forecast Assumptions and Methods
    • 3.4.3. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of MG
    • 3.4.4. Forecast Assumptions and Methods - Diagnosed Prevalent Cases of MG by Severity
  • 3.5. Epidemiological Forecast for MG (2018-2028)
    • 3.5.1. Diagnosed Prevalent Cases of MG
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of MG
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of MG
    • 3.5.4. Diagnosed Prevalent Cases of MG by Severity
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head and EVP of Healthcare Operations and Strategy
  • 4.3. About GlobalData
  • 4.4. Contact Us
  • 4.5. Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.